Abstract
In recent years, sialic acid is considered to be a possible marker for cardiovascular
diseases. The aim of this study was to investigate the effect of two different treatment
periods of fenofibrate (CAS 49562-28-9) on serum, heart and liver sialic acid levels
in experimental hypercholesterolemia. Serum, heart and liver total sialic acid levels
were determined by Warren’s thiobarbituric acid (TBA) method and serum lipid levels
by commercial kits at the end of the fenofibrate treatment for 3 and 6 weeks.
Fenofibrate treatment reduced serum total sialic acid levels significantly in the
control and hypercholesterolemic groups at the end of the 3rd week and only in the control group at the end of the 6th week.
Serum sialic acid levels of fenofibrate-treated hypercholesterolemic rats in the 6-week
period were significantly higher than those in the 3-week period. Neither the hypercholesterolemic
diet nor fenofibrate had any significant effect on heart and liver sialic acid levels.
In conclusion, decreased serum sialic acid levels in control and hypercholesterolemic
groups by fenofibrate short-term treatment may contribute to the decreased risk of
cardiovascular diseases that accompanies the hypercholesterolemic complications. The
decreased serum sialic acid levels further indicate the clinical efficacy of fenofibrate
as an anti-inflammatory agent.
Key words
CAS 49562-28-9 - Fenofibrate, effect on sialic acid levels - Hypercholesterolemia,
experimental - Hypolipidemic drugs Sialic acid, in heart and liver
